Quality assessment and stability study of compounded furosemide syrup
DOI:
https://doi.org/10.15587/2519-4852.2017.113517Keywords:
furosemide, syrup, compounded preparations, in-pharmacy control, stability, quality assessment, thin layer chromatographyAbstract
Compounded oral preparations, made with use of manufactured products as sources of active pharmaceutical ingredients, are characterized by short beyond-use-dates due to their instability.
Aim: The aim of this study is to investigate the physical, chemical and microbiological stability of compounded furosemide syrups within a 30 days period.
Methods: Batches of 5 mg/ml compounded syrups, using furosemide substance and commercial tablets (two brands) as sources of active pharmaceutical ingredients, were stored in the dark at 5±3 °C and 23±2 °C and examined at days 0, 7, 15, 23, and 30 for changes in physical (pH, formation of colour, gas, odour and changes in viscosity), chemical and microbial stability. A stress test was conducted in order to distinguish signs of chemical instability using a stability-indicating thin-layer chromatographic method. Bacterial inoculation of these samples were examined for microbial stability based on the total aerobic microbial count (TAMC <100), the total combined yeasts/moulds count (TYMC <10) and absence of Escherichia coli.
Results: Throughout the storage period the investigated syrups showed no extra spots on the chromatogram, no significant changes in pH, colour, odour, gas formation, viscosity. On day 30, the content (≥99.3%) of furosemide, total aerobic microbial count (< 102), total combined yeasts/moulds count (<101) in studied samples were within acceptable limits. Stressed samples showed presence of extra and diminished spots.
Conclusions: Extemporaneous syrups of furosemide substance and dispersed furosemide tablets, stored in glass bottles in the dark at 5±3 °C and 23±2 °C, was found to be physically, chemically and microbiologically stable for at least 30 daysReferences
- Giam, J. A., McLachlan, A. J. (2008). Extemporaneous product use in paediatric patients: a systematic review. International Journal of Pharmacy Practice, 16 (1), 3–10. doi: 10.1211/ijpp.16.1.0002
- Allen, L. V. (2016). The Art, Science, and Technology of Pharmaceutical Compounding. Washington D.C.: American Pharmacists Association. doi: 10.21019/9781582122632
- Diorio, L., Thomas, D. (2009). Evaluating stability data understanding beyond-use dating for compounded sterile preparations. Pharmacy, purchasing & products, 4, 12–14.
- Pharmaceutical Compounding. The United States Pharmacopeia (2016). Rockville: The United States Pharmacopeial Convention, 2016.
- Mason, B., Parker, D., Lott, R. (2013). Capstone pharmacy review. Burlington: Jones & Bartlett Learning, 107–108.
- Pharmaceutical Compounding – Nonsterile Preparations <795>. Available at: http://www.usp.org/compounding/general-chapter-795
- Stoehr, N. (2017). Compound Academy Solutions and Suspensions. American College of Apothecaries, 22–71. Available at http://acainfo.org/wp-content/uploads/2017/07/L5-Compound-Academy-Solutions-and-Suspensions.pdf
- McNulty, J. P., Muller, G. (2014). Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice. Int J Pharm Compd., 18 (30), 190–200.
- Allen, L. V. (2011). Stability of Extemporaneously Prepared Oral Liquid Formulations – Part VIII. Secundum Artem, 16 (3), 1–6.
- Salgado, A. C., Rosa, L., Duarte, A., Almeida, A. J. (2005). Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded paediatric formulations. The European Journal of Hospital Pharmacy Science, 11 (3), 68–73.
- Niazi, K. (2009). Handbook of Pharmaceutical Manufacturing Formulations: Liquid Products. New York: Informa Healthcare. doi: 10.3109/9781420081244
- Alfred-Ugbenbo, D., Zdoryk, O. A., Georgiyants, V. A., Schnatz, R. (2016). Compounding in Nigeria. International Journal of Pharmaceutical Compounding, 20 (3), 189–192.
- Allen, L. V. (1997). A formulation for preparing Syrup NF. International Journal of Pharmaceutical Compounding, 2 (1), 111.
- State Pharmacopoeia of Ukraine (2014). Kharkiv: State Enterprise «Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines».
- Alfred-Ugbenbo, D., Zdoryk, O. A., Georgiyants, V. A. (2017). Validation of analytical method for determination of furosemide in extemporaneous syrup. Medical and Clinical Chemistry, 19 (2), 5–11. doi: 10.11603/mcch.2410-681x.2017.v0.i2.7859
- European pharmacopoeia (2011). Strasbourg: Council of Europe.
- Florence, A., Siepmann, J. (2009). Modern Pharmaceutics. CRC Press, 1216. doi: 10.1201/b14445
- Aremu, O. I., Oduyela, O. O. (2015). Evaluation of metronidazole suspensions. African Journal of Pharmacy and Pharmacology, 9 (12), 439–450. doi: 10.5897/ajpp2014.4036
- Lam, M. S. H. (2011). Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs. Pharmacotherapy, 31 (2), 164–192. doi: 10.1592/phco.31.2.164
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Deghinmotei Alfred-Ugbenbo, Oleksandr Zdoryk, Viktoria Georgiyants
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.